Barclays maintains Certara at Equal-Weight, raises price target to $12 from $9

Barclays kept Certara at Equal-Weight, raising its price target to $12 from $9, a 33.3% increase. This implies a 1.5% downside from the Nov 5 close of $12.18. Recent analyst price targets for Certara range from $9 to $12.

Original reporting
Published Nov 6, 2026, 4:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Certara at Equal-Weight, raises price target to $12 from $9 — source image
Decision brief

The 30-second read

$CERTBullishLow
01

Why it matters

The analyst upgrade may prompt short‑term buying pressure, but the effect is modest given the small market cap.

02

Market read

A modest analyst upgrade that could slightly lift Certara's share price.

03

What to watch

Potential dilution from future financing or regulatory setbacks could offset the bullish view.

Relevance 5/10Novelty 5/10Timing: today

Background

Barclays maintains an equal‑weight rating on Certara while increasing its price target.

Company-level read

Ticker impact

$CERTBullishMedium confidence
Context

Barclays raised Certara's price target to $12 from $9, indicating a bullish analyst view.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The target raise reflects improved expectations and may attract buying interest.

Market effects

May lift sentiment in the biotech/clinical‑trial sector as analysts show confidence.

Limited to US markets where Certara trades.

Minimal global impact beyond the stock itself.

Counterpoint

The target raise could be premature if upcoming trial data disappoints.

Key entities

  • Barclays

    Equity research firm issuing the price target raise.

  • Certara

    US‑listed biotech firm (ticker CERT).

Related articles

$CERTMedAI 8/10

An Idle Mill and Old Open Pits Draw a New Plan in Southern Argentina

Cerrado Gold Inc. (TSX.V: CERT) (OTCQX: CRDOF) acquired a past-producing mine in Argentina for $20M, aiming to restart operations by 2027. The mine previously produced 1.4M gold equivalent ounces, with peak output of 137,500 ounces in 2011. The company plans a $40,000m drill program for a resource estimate, funded by its existing Santa Cruz operation.

$CERTHigh

Certara Software Revenue Jumps 11% as Services Decline

Certara Inc. (CERT) reported Q3 2026 software revenue growth of 11% to $48.8M, while services revenue declined 2% to $46.1M. Total revenue rose 4% to $94.9M, and net loss narrowed to $3.6M. Adjusted EBITDA increased 6% to $30.2M. The company maintained its full-year revenue growth forecast of 2-3% and updated its adjusted earnings outlook to 31-34 cents per share.

$CERTMed

Why Did Certara (CERT) Shares Climb After Its Latest Update?

Certara (CERT) reported Q3 2026 revenue of $94.9M, up from $90.89M a year earlier, with net income of $5.59M. However, nine-month revenue of $282.26M showed a net loss of $58.44M. Shares rose 9.83% in one day and 35.94% in 30 days, with a year-to-date return of 39.36%. The company's fair value is estimated at $8.71, suggesting a 40% overvaluation. Certara's AI-driven platforms and acquisitions aim to boost revenue and margins.

$CERTMed

Certara Inc (CERT) Q3 2026 Earnings Call Highlights: Software Growth Accelerates as Margins Expand

Certara Inc (CERT) reported Q3 2026 earnings with software revenue growth of 11% but services revenue declined 2% YoY to $46.1M. Full-year 2026 revenue growth guidance was narrowed to 2%-3%. CEO Jon Resnick highlighted cost savings exceeding $12M and strong software demand across customer tiers. The company is transitioning to a cloud-based model and investing in AI initiatives, expecting growth in 2027. GAAP net loss was $3.6M, and adjusted EPS remained flat at $0.09 YoY.

$CERTMed

Certara, Inc. Q3 2026 Earnings Call Summary

Certara reported 11% organic software revenue growth in Q3 2026, its first double-digit increase in two years. The company divested its Regulatory and Medical Writing business to focus on high-growth areas and reorganized operations. Management expects 2%-3% full-year revenue growth, with software outperforming services. AI capabilities and APAC market expansion are seen as growth drivers for 2027.